Cesca Therapeutics Inc., the Rancho Cordova-based medical equipment firm, on Tuesday reported a loss of $4.8 million, or 12 cents per share, for its fiscal third quarter that ended March 31.
That compares with a loss of $1.9 million, or 7 cents a share, in the same period of 2014.
The year-over-year increase in net losses was related to substantial investments in development of clinical programs and increased legal and professional costs, the company said. Net quarterly revenue was $4 million, matching the year-ago total.
Cesca does research, development and commercialization of products used in regenerative medicine, including automated blood and bone marrow processing systems.
Sign Up and Save
Get six months of free digital access to The Sacramento Bee
Cesca stock closed Tuesday at 92 cents a share, up 2 cents for the day.
Cesca formerly operated as ThermoGenesis Corp. It was renamed in 2014 after finalizing its merger with Los Angeles-based TotipotentRX Corp.